Market Overview

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Share:
Related RGEN
10 Stocks That Rallied Four Days, Then Sold Off Yesterday
15 Stocks Which Rallied Four Days, Then Sold Off Yesterday
Related PFE
Benzinga's Top Initiations
The Market In 5 Minutes: Payrolls, Smith & Wesson Earnings And Starbucks' CEO Change
Guggenheim neutral on Pfizer (Seeking Alpha)

Repligen Corporation (NASDAQ: RGEN) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA).

Posted-In: News FDA

 

Related Articles (RGEN + PFE)

View Comments and Join the Discussion!